Literature DB >> 19224168

Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance.

Yonghua Wang1, Qianyuan Zhuang, Siwei Zhou, Zhiquan Hu, Ruzhu Lan.   

Abstract

B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and immune escape of bladder cancer, B7-H1 expression in 50 cases of bladder cancer was detected by using immunohistochemical method. Survival curves were constructed using the Kaplan-Meier method and independent prognostic factors were evaluated using the Cox regression model. Our results showed that the positive rate of B7-H1 immunostaining in normal bladder tissue and bladder cancer was 0 and 72% respectively. The expression of B7-H1 was strongly associated with the pathological grade, clinical stage and recurrence (P<0.05). The survival rate was significantly lower in patients with B7-H1 positive group than in those with B7-H1 negative group and multi-variable analysis revealed that B7-H1 could be regarded as an independent factor in evaluating the prognosis of bladder cancer. It is concluded that the expression of B7-H1 is strongly associated with neoplastic progression and prognosis of bladder cancer. The manipulation of B7-H1 may become a beneficial target for immunotherapy in human bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224168     DOI: 10.1007/s11596-009-0116-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  20 in total

1.  B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.

Authors:  Junko Hori; Mingcong Wang; Megumi Miyashita; Keiko Tanemoto; Hiroshi Takahashi; Toshitada Takemori; Ko Okumura; Hideo Yagita; Miyuki Azuma
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Authors:  Tyler J Curiel; Shuang Wei; Haidong Dong; Xavier Alvarez; Pui Cheng; Peter Mottram; Roman Krzysiek; Keith L Knutson; Ben Daniel; Maria Carla Zimmermann; Odile David; Matthew Burow; Alan Gordon; Nina Dhurandhar; Leann Myers; Ruth Berggren; Akseli Hemminki; Ronald D Alvarez; Dominique Emilie; David T Curiel; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

3.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

Authors:  Hazem Ghebeh; Shamayel Mohammed; Abeer Al-Omair; Amal Qattan; Cynthia Lehe; Ghofran Al-Qudaihi; Naser Elkum; Mohamed Alshabanah; Suad Bin Amer; Asma Tulbah; Dahish Ajarim; Taher Al-Tweigeri; Said Dermime
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

4.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

5.  Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Authors:  Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

6.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Authors:  Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

7.  B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.

Authors:  Jun Konishi; Koichi Yamazaki; Miyuki Azuma; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

8.  Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Authors:  Christian Blank; Juergen Kuball; Simon Voelkl; Heinz Wiendl; Bernd Becker; Bernhard Walter; Otto Majdic; Thomas F Gajewski; Mathias Theobald; Reinhard Andreesen; Andreas Mackensen
Journal:  Int J Cancer       Date:  2006-07-15       Impact factor: 7.396

9.  Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection.

Authors:  Soumita Das; Giovanni Suarez; Ellen J Beswick; Johanna C Sierra; David Y Graham; Victor E Reyes
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

10.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.

Authors:  Sabine Wintterle; Bettina Schreiner; Meike Mitsdoerffer; Dagmar Schneider; Lieping Chen; Richard Meyermann; Michael Weller; Heinz Wiendl
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  14 in total

1.  IL-10 enhances promoter activity of ILT4 gene and up-regulates its expression in THP-1 cells.

Authors:  Xiaoli Xu; Ping Zou; Lijuan Chen; Guannan Jin; Hao Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

Review 2.  Emerging immunotherapies for bladder cancer.

Authors:  Joseph W Kim; Yusuke Tomita; Jane Trepel; Andrea B Apolo
Journal:  Curr Opin Oncol       Date:  2015-05       Impact factor: 3.645

Review 3.  New and promising strategies in the management of bladder cancer.

Authors:  Andrea B Apolo; Nicholas J Vogelzang; Dan Theodorescu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

Review 4.  [Immunological biomarker research in uro-oncology-using the example of urothelial cancer].

Authors:  Markus Eckstein
Journal:  Urologie       Date:  2022-05-30

Review 5.  Implications of the tumor immune microenvironment for staging and therapeutics.

Authors:  Janis M Taube; Jérôme Galon; Lynette M Sholl; Scott J Rodig; Tricia R Cottrell; Nicolas A Giraldo; Alexander S Baras; Sanjay S Patel; Robert A Anders; David L Rimm; Ashley Cimino-Mathews
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

Review 6.  PD-L1 and Survival in Solid Tumors: A Meta-Analysis.

Authors:  Pin Wu; Dang Wu; Lijun Li; Ying Chai; Jian Huang
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

7.  Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.

Authors:  Yaxiong Zhang; Shiyang Kang; Jianfei Shen; Jiaxi He; Long Jiang; Wei Wang; Zhihua Guo; Guilin Peng; Gang Chen; Jianxing He; Wenhua Liang
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

8.  Prognostic value of PD -L1 expression in patients with primary solid tumors.

Authors:  Xiao Xiang; Peng-Cheng Yu; Di Long; Xiao-Li Liao; Sen Zhang; Xue-Mei You; Jian-Hong Zhong; Le-Qun Li
Journal:  Oncotarget       Date:  2017-12-22

Review 9.  Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.

Authors:  Qianqian Wang; Fang Liu; Lei Liu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

Review 10.  PD-L1 expression in human cancers and its association with clinical outcomes.

Authors:  Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.